OPKO Health, Inc. (NASDAQ:OPK) Short Interest Down 70.0% in April

OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) saw a large decline in short interest during the month of April. As of April 15th, there was short interest totalling 34,960,000 shares, a decline of 70.0% from the March 31st total of 116,490,000 shares. Currently, 11.5% of the shares of the stock are short sold. Based on an average daily volume of 4,900,000 shares, the days-to-cover ratio is currently 7.1 days.

OPKO Health Stock Down 1.4 %

Shares of OPKO Health stock traded down $0.02 on Wednesday, reaching $1.38. The company's stock had a trading volume of 2,580,939 shares, compared to its average volume of 3,888,366. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. The company has a market capitalization of $926.74 million, a price-to-earnings ratio of -7.26 and a beta of 1.78. The firm's fifty day simple moving average is $1.63 and its two-hundred day simple moving average is $1.57. OPKO Health has a 52 week low of $1.15 and a 52 week high of $2.04.

OPKO Health (NASDAQ:OPK - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.03). OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The business's revenue was down 13.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.12) EPS. Equities analysts anticipate that OPKO Health will post -0.25 earnings per share for the current year.

Insider Activity at OPKO Health

In related news, CEO Phillip Md Et Al Frost acquired 200,000 shares of the business's stock in a transaction dated Monday, March 17th. The shares were bought at an average price of $1.74 per share, with a total value of $348,000.00. Following the transaction, the chief executive officer now directly owns 213,501,448 shares of the company's stock, valued at $371,492,519.52. This trade represents a 0.09 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last three months, insiders have purchased 767,434 shares of company stock valued at $1,238,312. 49.69% of the stock is owned by insiders.

Institutional Investors Weigh In On OPKO Health

Hedge funds have recently bought and sold shares of the business. Cerity Partners LLC purchased a new stake in shares of OPKO Health in the first quarter worth approximately $36,000. Pallas Capital Advisors LLC acquired a new position in OPKO Health during the 1st quarter valued at approximately $43,000. Wealth Enhancement Advisory Services LLC increased its holdings in shares of OPKO Health by 75.3% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company's stock valued at $42,000 after purchasing an additional 12,417 shares during the period. Cibc World Markets Corp purchased a new stake in shares of OPKO Health in the 4th quarter valued at $45,000. Finally, Zacks Investment Management purchased a new stake in OPKO Health in the fourth quarter valued at $49,000. Hedge funds and other institutional investors own 64.63% of the company's stock.

Analyst Upgrades and Downgrades

OPK has been the topic of a number of recent analyst reports. Barrington Research reiterated an "outperform" rating and set a $2.25 target price on shares of OPKO Health in a research note on Wednesday, March 12th. HC Wainwright reissued a "buy" rating and set a $3.00 price objective on shares of OPKO Health in a report on Monday, April 7th. JPMorgan Chase & Co. assumed coverage on shares of OPKO Health in a report on Friday, April 25th. They issued a "neutral" rating for the company. Finally, StockNews.com upgraded shares of OPKO Health from a "sell" rating to a "hold" rating in a research report on Monday, March 3rd. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $2.75.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.